Access to treatment for Hepatitis C
Sirianni Youtz Spoonemore Hamburger is representing individuals who have been denied insurance coverage for treatment of their Hepatitis C with Harvoni® and other direct acting anti-viral drugs (“DAAs”). Harvoni and other DAAs are the standard of medical care for the treatment of all HCV. This includes treatment of all individuals irrespective of the individual’s fibrosis score. Treatment guidelines approved by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America confirm that Harvoni and other DAAs should not be reserved for only individuals with fibrosis scores of F3 and F4. See http://hcvguidelines.org/. Rather, the standard of care is treat “all patients with chronic HCV infection, except those with short life expectancies that cannot be remediated by treated HCV, by transplantation, or by other directed therapy.” See http://hcvguidelines.org/full-report/when-and-whom-initiate-hcv-therapy. Treating all patients is the standard of care in the community and the only obstruction to treatment today is insurance company approval. Please feel free to contact us if you have been denied insurance coverage for this curative therapy.